DIFFERENCE IN RESPONSE TO ORDINARY CHEMOTHERAPY IN PATIENT WITH MSI STABLE AND INSTABLE DISEASE AMONG COLON CANCER CASES

Abstract

Abstract

Colonic carcinoma is the most commonly diagnosed cancer-related morbidity and mortality worldwide with high mortality. Colorectal cancer (CRC) can be classified according to the chromosomal-instability pathway (a microsatellite-stable (MSS) pathway) and the microsatellite-instability (MSI) pathway, MSI-H CRCs have better stage-adjusted survival. A prospective study , 28 patient with colon cancer enrolled in the study, for each patient the Microsatellite Instability (MSI) was tested, and the patient were followed for 36 months to detect the survival rate. Patients referred to the Salahadeen Cancer Management Center in Iraq underwent testing for Microsatellite Instability (MSI). The MSI stable found among 11(61.1%) and MSI instable found among 7(38.9%). the MSI instable was non significantly higher among male patients 5(41.7%), common in younger age group < 50 years. Most of the nod negative were significantly had MSI instable characteristics 5(83.3%), most of the T2 staging were non significantly had MSI stable characteristics 8(80.0%), while MSI instable commonly found among T4 stage 3(60%).  Most of the MSI instable commonly found among grade III and IV 3(75%), and 2(100%) respectively. The patient with MSI instable characteristics significantly had longer relapse free survival time 26.8 ± 4.5 months than those with MSI stable character 21.36 ± 1.01. The patient with MSI characteristics had better prognosis and longer time of relapse free survival than those with MSS patient. A study with larger sample size and longer follow up time was needed to relate the stage of the disease with the prognosis of the treatment